**Supplementary Materials**

***ROS1* mutations promote an immunosuppressive tumor microenvironment via *MYC* to confer immune evasion in head and neck cancer**

**Chao Fang1,2,#, Qin Zhang3,#, Rui Fang1,2,#, Ying Li1,2, Jing Bai1,2, Xiaojing Huang1, Jingting Lu1,** **Dongsheng Chen3, Yanxiang Zhang3, Zuhong Chen1,2**

1The School of Clinical Medicine, Fujian Medical University, Fuzhou 350000, Fujian, China.

2Department of Otolaryngology-Head & Neck Surgery, The First Hospital of Putian, Putian 351100, Fujian, China.

3State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., Nanjing 210018, Jiangsu, China.‌

#Authors contributed equally.

**Correspondence to:**Prof. Zuhong Chen, The School of Clinical Medicine, Fujian Medical University, No. 88 Jiaotong Road, Fuzhou 350000, Fujian, China. E-mail: [zuhongchen@126.com](mailto:zuhongchen@126.com) (lead contact); Dr. Yanxiang Zhang, State Key Laboratory of Neurology and Oncology Drug Development, Jiangsu Simcere Diagnostics Co., Ltd., No. 699-18 Xuanwu Street, Nanjing 210018, Jiangsu, China. E-mail: [yxzhang2008@hotmail.com](mailto:yxzhang2008@hotmail.com)

****

**Supplementary Figure 1.** Kaplan-Meier survival analysis based on *ROS1* status.